Oral semaglutide delivers significant weight loss in OASIS trials, offering needle-free obesity therapy.
Celestine Van Sertima, PharmD Candidate
Advertisement
Articles by Celestine Van Sertima, PharmD Candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
3
FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Advanced NSCLC
5